uPAR antagonists (Glaxo Wellcome)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameuPAR antagonists (Glaxo Wellcome)
Drug Alias Nameurokinase receptor antagonists (Glaxo Wellcome)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionUrokinase plasminogen activator modulators
TargetsUrokinase plasminogen activator
Therapy Area/IndicationsNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxo Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxo Group Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A